

Department of Dermatology


New Staff Arrivals

Welcome New Dermatology Faculty



We are pleased to welcome **Anusha Mohan Kumar**, MD, MSc, to the Department of Dermatology. Dr. Kumar's special interests include the intersection of skin and gastrointestinal diseases, with a particular expertise in managing cutaneous side effects of medications used to treat inflammatory bowel disease. Dr. Kumar will serve as our inaugural Director of Gastroenterology–Dermatology (GI-Derm) and will lead a GI-Derm specialty clinic on Tuesday afternoons in the Shapiro Clinic, while continuing her clinical research in this area.

She earned her medical degree from Stanford University School of Medicine, completed her internship at Brigham and Women's Hospital, and her dermatology residency at Mass General Brigham/Massachusetts General Hospital.



This fall, we welcomed **J. Michael Yardman-Frank**, MD, MPH, to the Department of Dermatology. Dr. Yardman-Frank sees patients in our Shapiro, Chestnut Hill, and Chelsea offices and spends three months each year attending on the inpatient consultation service. He cares for both general and cosmetic dermatology patients and participates in the Friday Resident Excision Clinic in Dermatologic Surgery twice per month.

Dr. Yardman-Frank has special interests in global health and expanding access to dermatologic care for underserved populations. He serves as our inaugural Director of Global and Community Health Dermatology, while continuing his research in these areas. In addition, he leads a new specialty clinic focused on Pigmentary, Granulomatous, and Lichenoid Disorders (the "PGL Clinic"), held on Tuesday mornings in the Shapiro Clinic.

Dr. Yardman-Frank earned his medical degree from the University of New Mexico School of Medicine and his master's in public health from the Johns Hopkins Bloomberg School of Public Health. He completed his internship at UMass Chan Medical School and his residency in Dermatology at Massachusetts General Hospital.

Department of Dermatology

New Staff Arrivals


Welcome New Dermatology Faculty, Cont.



Sepideh Ashrafzadeh, MD, joined the Department of Dermatology on August 1 and is seeing patients in our Shapiro, Chestnut Hill, and Chelsea offices.

Dr. Ashrafzadeh serves as our new Director of High-Risk Skin Cancer and leads a specialty clinic dedicated to the care of these patients on Wednesday afternoons in Shapiro. In addition, she practices general and cosmetic dermatology and will attend the Friday Resident Excision Clinics in Dermatologic Surgery on a monthly basis.

Dr. Ashrafzadeh earned her medical degree from Harvard Medical School, completed her internship at Cambridge Health Alliance, and her residency in dermatology at Massachusetts General Hospital.



Welcome **Jamie Katy Hu, MD**, who is seeing patients in our Shapiro, Chestnut Hill, and Needham offices.

Dr. Hu will serve as our new Director of Hair Loss and will launch the department's first-ever specialty clinic dedicated to the care of patients with hair loss, held on Wednesday mornings in Shapiro. She recently completed a fellowship in laser and cosmetic dermatology and will practice cosmetic and general dermatology in our Needham and Chestnut Hill offices.

Dr. Hu earned her medical degree from Yale University School of Medicine, completed her internship at Yale–New Haven Hospital, residency in dermatology at the University of Miami/Jackson Health System, and fellowship at Massachusetts General Hospital.

Department of Dermatology

Awards & Honors

HMS 2025 Charles McCabe Faculty Prize



We are excited to share that **Katherine Brag**, MD, has been awarded the 2025 Charles McCabe Faculty Prize for Excellence in Clinical Teaching in recognition of her outstanding dermatology teaching in the Medicine Clerkship at Beth Israel Deaconess Medical Center.

Congratulations Physician Leadership Program Graduates



Congratulations to **Tina Porter**, MD, who was one of 13 recent graduates of the 2024-25 BILH Physician Leadership Program (PLP), a 12-month leadership development program designed to help physicians strengthen their leadership competencies.

Dr. Porter's PLP project implemented a quality improvement methodology to streamline the check-in and check-out processes in our General Dermatology and Dermatology Surgery clinics. She said of the PLP program, "I have been truly impressed by the breadth and depth of this course, including the didactic teachings and the coaching. There is not enough leadership training in our medical training, and I think this can hinder career development and growth. I was really impressed with all my colleagues' ability to share personal details, particularly during the two-day retreat in January. I felt joy watching my colleagues' experience personal growth over these intensive two days."

Department of Dermatology

Publications
Jul - Sept 2025

Alnajjar NF, Davies OMT, Gochoco A, Lyle SR, **Iriarte C**. Livedo racemosa and spontaneous retinal detachment as presenting signs of paraneoplastic sarcoid vasculitis. *JAAD Case Rep*. 2025 Aug 19;65:1-3. doi: 10.1016/j.jdcr.2025.08.009. PMID: 41078421; PMCID: PMC12513318.

Patin E, Santiago Mangual KP, Murase JE, **Kourosh AS**. Reflecting on Dark Waters: A call for awareness and investigation of forever chemicals contacting the skin. *J Am Acad Dermatol*. 2025 Jun 6:S0190-9622(25)02236-4. doi: 10.1016/j.jaad.2025.05.1443. Epub ahead of print. PMID: 40484136.

Bruess GES, Barry KK, **Olsen GM**, Foschi CM, Cook E, Liegl M, Pan AY, Lalor L. Evaluating Outcomes of Live-Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis. *Pediatr Dermatol*. 2025 Sep 2. doi: 10.1111/pde.70033. Epub ahead of print. PMID: 40898756.

Alavi A, Reguiat Z, Jemec GBE, Gottlieb AB, Wozniak MB, Uhlmann L, Fan H, Llobet Martinez A, Bruin G, Thomas N, Alarcon I, Bieth B, Ravichandran S, **Kimball AB**. Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies. *Int J Dermatol*. 2025 Aug 21. doi: 10.1111/ijd.70025. Epub ahead of print. PMID: 40839197.

Forman S, Kephart L, Ota T, Pawlikowski J, Jiang J, **Kimball AB**. A Phase 2, Randomized, Placebo-Controlled Study of Bermekimab in Moderate-to-Severe Hidradenitis Suppurativa. *J Invest Dermatol*. 2025 Aug 25:S0022-202X(25)02356-5. doi: 10.1016/j.jid.2025.07.032. Epub ahead of print. PMID: 40865678.

Kilgour JM, Landy H, **Kimball AB**, Resnik BI, Anadkat MJ, Dhawan S, de Souza M, Sarin KY. The P2X7-NLRP3 inflammasome inhibitor AZD9056 has no significant effect on hidradenitis suppurativa clinical disease activity but restores cytokine production in peripheral blood mononuclear cells: Results of a phase 2 trial. *J Am Acad Dermatol*. 2025 Sep 27:S0190-9622(25)02902-0. doi: 10.1016/j.jaad.2025.09.079. Epub ahead of print. PMID: 41022330.

Department of Dermatology

Publications
Jul - Sept 2025

Ingram JR, Wozniak MB, Passera A, Uhlmann L, Martinez AL, Bechara FG, Bender RH, McLeod LD, Martin S, Moreno SG, Marvel J, Ravichandran S, **Kimball AB**. The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient reported outcomes for hidradenitis suppurativa. Br J Dermatol. 2025 Aug 5:ljaf307. doi: 10.1093/bjd/ljaf307. Epub ahead of print. PMID: 40794600.